210 related articles for article (PubMed ID: 19075280)
21. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
23. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
25. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
[TBL] [Abstract][Full Text] [Related]
26. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
Lamanna N; Kalaycio M; Maslak P; Jurcic JG; Heaney M; Brentjens R; Zelenetz AD; Horgan D; Gencarelli A; Panageas KS; Scheinberg DA; Weiss MA
J Clin Oncol; 2006 Apr; 24(10):1575-81. PubMed ID: 16520464
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine in chronic lymphocytic leukaemia.
Elter T; Hallek M; Engert A
Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
30. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
31. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ; O'Brien S; Albitar M; Lerner S; Plunkett W; Giles F; Andreeff M; Cortes J; Faderl S; Thomas D; Koller C; Wierda W; Detry MA; Lynn A; Kantarjian H
J Clin Oncol; 2005 Jun; 23(18):4079-88. PubMed ID: 15767648
[TBL] [Abstract][Full Text] [Related]
32. Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
Hillmen P
Semin Oncol; 2004 Feb; 31(1 Suppl 2):22-6. PubMed ID: 15042531
[TBL] [Abstract][Full Text] [Related]
33. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Abrisqueta P; Villamor N; Terol MJ; González-Barca E; González M; Ferrà C; Abella E; Delgado J; García-Marco JA; González Y; Carbonell F; Ferrer S; Monzó E; Jarque I; Muntañola A; Constants M; Escoda L; Calvo X; Bobillo S; Montoro JB; Montserrat E; Bosch F
Blood; 2013 Dec; 122(24):3951-9. PubMed ID: 24124086
[TBL] [Abstract][Full Text] [Related]
34. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC
Blood; 2007 Jan; 109(2):405-11. PubMed ID: 17008537
[TBL] [Abstract][Full Text] [Related]
35. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia.
Schulz H; Klein SK; Rehwald U; Reiser M; Hinke A; Knauf WU; Aulitzky WE; Hensel M; Herold M; Huhn D; Hallek M; Diehl V; Engert A;
Blood; 2002 Nov; 100(9):3115-20. PubMed ID: 12384407
[TBL] [Abstract][Full Text] [Related]
36. Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia.
Bouvet E; Borel C; Obéric L; Compaci G; Cazin B; Michallet AS; Laurent G; Ysebaert L
Haematologica; 2013 Jan; 98(1):65-70. PubMed ID: 23065520
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
[TBL] [Abstract][Full Text] [Related]
38. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
39. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.
Tam CS; O'Brien S; Wierda W; Kantarjian H; Wen S; Do KA; Thomas DA; Cortes J; Lerner S; Keating MJ
Blood; 2008 Aug; 112(4):975-80. PubMed ID: 18411418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
